Abstract:Objective To investigate the clinical significance of KiF2A and RhoA in ovarian cancer. Methods Totally 20 cases of normal ovarian tissues, 25 cases of benign epithelial ovarian tumors, and 45 cases of ovarian cancer were involved in this study. Expression of KiF2A and RhoA protein was identified by immunohistochemistry. Association between KiF2A/RhoA and clinicopathological features was analyzed. Results The positive rates of KiF2A and RhoA protein expression in ovarian cancer tissues were increased compared with those in ovarian epithelial benign tumors and normal ovarian tissues (P < 0.05), while no significant difference in expression of KiF2A and RhoA between normal ovarian tissues and benign epithelial ovarian tumors was confirmed (P > 0.05). Expression of KiF2A was closely correlated to ovarian cancer staging and lymph node metastasis (P < 0.05). RhoA was closely associated with lymph node metastasis and histological grading (P < 0.05). The expression of KiF2A was positively correlated to expression of RhoA in ovarian cancer (r = 0.801, P < 0.05). Conclusions High expression of KiF2A and RhoA proteins in ovarian cancer tissues may be involved in the development of ovarian cancer.